Meeting
2015 ASCO Annual Meeting
Common and rare EGFR mutations (EGFRm) in the RADIANT trial: Final follow-up with 5 year data.
Authors
Frances A. Shepherd
Princess Margaret Cancer Centre, Toronto, ON, Canada
Frances A. Shepherd , Wilfried Ernst Erich Eberhardt , Nasser K. Altorki , Mary E.R. O'Brien , Joe Wang , Jun Wu , Stan Gill , Kenneth Iwata , Frank C Richardson , Julie D. Horan , Margaret A. Foley , Karen Kelly
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Local-Regional Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT00373425
Citation
J Clin Oncol 33, 2015 (suppl; abstr 7539)
DOI
10.1200/jco.2015.33.15_suppl.7539
Abstract #
7539
Poster Bd #
286
Abstract Disclosures
Similar Posters
Poster
2012 ASCO Annual Meeting
Vinorelbine plus cisplatin versus gefitinib in resected non-small cell lung cancer haboring activating EGFR mutation (WJOG6410L).
First Author: Hirohito Tada
Poster
2011 ASCO Annual Meeting
The SELECT trial: A multicenter phase II trial of adjuvant erlotinib (E) in patients with resected, early-stage non-small cell lung cancer (NSCLC) and confirmed mutations in the epidermal growth factor receptor (EGFR).
First Author: N. A. Pennell
Poster
2012 ASCO Annual Meeting
The SELECT study: A multicenter phase II trial of adjuvant erlotinib in resected epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
First Author: Joel W. Neal
Poster
2024 ASCO Annual Meeting
Safety and efficacy of osimertinib in patients with NSCLC and uncommon tumoral EGFR mutations: A systematic review and meta-analysis.
First Author: Jonathan N. Priantti